Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

Key developments in non-metastatic and metastatic hormone-sensitive prostate...

Dr Eleni Efstathiou, Prof Nicholas Mottet, Dr Andrew Armstrong and Prof Maria...

Key developments in non-metastatic and metastatic hormone-sensitive prostate cancer ( Dr Eleni Efstathiou, Prof Nicholas Mottet, Dr Andrew Armstrong and Prof Maria De Santis )

Novel fusion proteins to target PD-L1 in HPV associated cancers

Dr James Gulley - Center for Cancer Research, Washington, USA

Novel fusion proteins to target PD-L1 in HPV associated cancers ( Dr James Gulley - Center for Cancer Research, Washington, USA )

Phase I study results of M7824 for patients with HPV associated cancers

Dr Julius Strauss - Center for Cancer Research, Washington, USA

Phase I study results of M7824 for patients with HPV associated cancers ( Dr Julius Strauss - Center for Cancer Research, Washington, USA )

ASCO 2018: Novel treatment strategies in prostate cancer therapeutics

Prof Karim Fizazi and Dr Neal Shore

ASCO 2018: Novel treatment strategies in prostate cancer therapeutics ( Prof Karim Fizazi and Dr Neal Shore )

ASCO 2018: Latest developments in non-metastatic and metastatic castration...

Dr Neal Shore, Dr Simon Chowdhury, Prof Matthew Smith and Prof Boris Hadaschik

ASCO 2018: Latest developments in non-metastatic and metastatic castration-resistant prostate cancer ( Dr Neal Shore, Dr Simon Chowdhury, Prof Matthew Smith and Prof Boris Hadaschik )

Early results from a 3rd gen EGFR-TKI in advanced NSCLC

Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, the Republic of Korea

Early results from a 3rd gen EGFR-TKI in advanced NSCLC ( Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, the Republic of Korea )

ASCO 2018: Latest in bladder cancer treatments

Prof Thomas Powles & Prof Shahrokh Shariat

ASCO 2018: Latest in bladder cancer treatments ( Prof Thomas Powles & Prof Shahrokh Shariat )

Zoptarelin no better than doxarubicin for second-line advanced endometrial...

Dr David Miller - The University of Texas Southwestern Medical Center

Zoptarelin no better than doxarubicin for second-line advanced endometrial cancer ( Dr David Miller - The University of Texas Southwestern Medical Center )

First-in-human phase 1 study of TAK-931 for solid tumours

Dr Toshio Shimizu - National Cancer Center Hospital (NCCH), Tokyo, Japan

First-in-human phase 1 study of TAK-931 for solid tumours ( Dr Toshio Shimizu - National Cancer Center Hospital (NCCH), Tokyo, Japan )

Matching mutations in tumours to precision medicine improves survival

Prof Apostolia Maria Tsimberidou - MD Anderson Cancer Center, Houston, USA

Matching mutations in tumours to precision medicine improves survival ( Prof Apostolia Maria Tsimberidou - MD Anderson Cancer Center, Houston, USA )

Development of blood tests for early lung cancer

Dr Geoffrey Oxnard - Dana-Farber Cancer Institute, Boston, USA

Development of blood tests for early lung cancer ( Dr Geoffrey Oxnard - Dana-Farber Cancer Institute, Boston, USA )

Editor’s Choice for May 2018

Prof Gordon McVie - Founding Editor, ecancer

Editor’s Choice for May 2018 ( Prof Gordon McVie - Founding Editor, ecancer )

More from ecancer